David M. Holtzman
#49,645
Most Influential Person Now
Medical researcher
David M. Holtzman's AcademicInfluence.com Rankings
David M. Holtzmanlaw Degrees
Law
#907
World Rank
#1177
Historical Rank
Common Law
#7
World Rank
#7
Historical Rank
David M. Holtzmanbiology Degrees
Biology
#1971
World Rank
#3179
Historical Rank
Neuroscience
#179
World Rank
#189
Historical Rank
Download Badge
Law Biology
David M. Holtzman's Degrees
- Bachelors Biology University of California, Berkeley
- PhD Neuroscience Stanford University
- Doctorate Medicine Harvard University
Similar Degrees You Can Earn
Why Is David M. Holtzman Influential?
(Suggest an Edit or Addition)According to Wikipedia, David M. Holtzman is an American physician-scientist known for his work exploring the biological mechanisms underlying neurodegeneration, with a focus on Alzheimer's disease. Holtzman is former Chair of the Department of Neurology, Scientific Director of the Hope Center for Neurological Disorders, and associate director of the Knight Alzheimer's Disease Research Center at Washington University School of Medicine in St. Louis, Missouri. Holtzman's lab is known for examining how apoE4 contributes to Alzheimer's disease as well as how sleep modulates amyloid beta in the brain. His work has also examined the contributions of microglia to AD pathology.
David M. Holtzman's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease (2011) (6818)
- NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018) (4523)
- Clinical and biomarker changes in dominantly inherited Alzheimer's disease. (2012) (2815)
- National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards (2006) (1436)
- The Role of Apolipoprotein E in Alzheimer's Disease (2009) (1368)
- The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. (2017) (1367)
- Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. (2000) (1322)
- Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria (2016) (1163)
- Alzheimer’s Disease: The Challenge of the Second Century (2011) (1159)
- Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease (2001) (1154)
- Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) (1148)
- Amyloid-β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle (2009) (1100)
- TREM2 lipid sensing sustains microglia response in an Alzheimer’s disease model (2015) (1013)
- Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance (2011) (997)
- Apolipoprotein E controls cerebrovascular integrity via cyclophilin A (2012) (993)
- Synaptic Activity Regulates Interstitial Fluid Amyloid-β Levels In Vivo (2005) (979)
- Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans (2006) (968)
- Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease (2008) (957)
- Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model (2002) (927)
- Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. (2007) (881)
- Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. (2000) (869)
- ApoE Promotes the Proteolytic Degradation of Aβ (2008) (856)
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging (2010) (777)
- Biomarker Modeling of Alzheimer’s Disease (2013) (763)
- Neuronal activity regulates the regional vulnerability to amyloid-β deposition (2011) (739)
- Selective Vulnerability of Late Oligodendrocyte Progenitors to Hypoxia–Ischemia (2002) (723)
- Apolipoprotein E in Alzheimer's disease and other neurological disorders (2011) (721)
- Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums (2018) (710)
- Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. (2012) (677)
- ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy (2017) (676)
- apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. (2008) (667)
- Multimodal techniques for diagnosis and prognosis of Alzheimer's disease (2009) (631)
- Transport Pathways for Clearance of Human Alzheimer's Amyloid β-Peptide and Apolipoproteins E and J in the Mouse Central Nervous System (2007) (626)
- TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease (2017) (610)
- Sleep and Alzheimer disease pathology—a bidirectional relationship (2014) (610)
- Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. (2005) (595)
- P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. (2005) (595)
- Endocytosis Is Required for Synaptic Activity-Dependent Release of Amyloid-β In Vivo (2008) (580)
- Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease (2002) (558)
- Three dimensions of the amyloid hypothesis: time, space and 'wingmen' (2015) (557)
- Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo (2006) (551)
- BDNF Protects the Neonatal Brain from Hypoxic-Ischemic InjuryIn Vivo via the ERK Pathway (2000) (550)
- Sleep quality and preclinical Alzheimer disease. (2013) (516)
- Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. (2001) (509)
- Caspase inhibitor affords neuroprotection with delayed administration in a rat model of neonatal hypoxic-ischemic brain injury. (1998) (508)
- Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease (2016) (496)
- Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* (2012) (492)
- TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques (2016) (491)
- Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study (2013) (488)
- Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (487)
- Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. (2009) (470)
- Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry (2001) (470)
- Loss of Intranetwork and Internetwork Resting State Functional Connections with Alzheimer's Disease Progression (2012) (464)
- In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life (2003) (456)
- Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of β-Amyloid in Mice with Alzheimer’s Disease Pathology (2012) (448)
- Mechanisms linking circadian clocks, sleep, and neurodegeneration (2016) (447)
- The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's Association workgroup (2011) (441)
- Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. (1996) (433)
- Neuronal activity regulates extracellular tau in vivo (2014) (418)
- ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions (2013) (417)
- ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition Evidence that ApoE Regulates Extracellular Aβ Metabolism In Vivo (2004) (415)
- Proteopathic tau seeding predicts tauopathy in vivo (2014) (412)
- Diffusion Tensor Imaging Reliably Detects Experimental Traumatic Axonal Injury and Indicates Approximate Time of Injury (2007) (408)
- ABCA1 Is Required for Normal Central Nervous System ApoE Levels and for Lipidation of Astrocyte-secreted apoE* (2004) (402)
- Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer’s disease (2016) (400)
- YKL-40: A Novel Prognostic Fluid Biomarker for Preclinical Alzheimer's Disease (2010) (393)
- Multi‐component apparent diffusion coefficients in human brain † (1999) (390)
- The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers (2011) (385)
- Plasma cortisol and progression of dementia in subjects with Alzheimer-type dementia. (2006) (370)
- Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis (2017) (369)
- Microglia Mediate the Clearance of Soluble Aβ through Fluid Phase Macropinocytosis (2009) (365)
- In situ atomic force microscopy study of Alzheimer’s β-amyloid peptide on different substrates: New insights into mechanism of β-sheet formation (1999) (365)
- p140 trk mRNA marks NGF-responsive forebrain neurons: Evidence that trk gene expression is induced by NGF (1992) (361)
- Sleep, circadian rhythms, and the pathogenesis of Alzheimer Disease (2015) (360)
- High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis (2019) (360)
- The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans (2019) (359)
- Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. (1995) (353)
- Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and - independent cellular responses in Alzheimer’s disease (2019) (353)
- Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. (1999) (349)
- Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. (2013) (347)
- White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network (2016) (341)
- Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease (2014) (335)
- Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. (2008) (333)
- GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease (2013) (332)
- Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease (2006) (329)
- Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease (2002) (325)
- Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ* (2006) (325)
- Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model (2000) (324)
- Cerebrospinal fluid tau and ptau181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's disease (2009) (323)
- Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) (319)
- Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease (2013) (318)
- Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer disease: a longitudinal study (2018) (316)
- Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of Amyloid β (2005) (314)
- Predicted alpha-helical regions of the prion protein when synthesized as peptides form amyloid. (1992) (314)
- Minocycline markedly protects the neonatal brain against hypoxic‐ischemic injury (2002) (311)
- In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice (2011) (310)
- Matrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism (2006) (310)
- Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets (2011) (305)
- A γ‐secretase inhibitor decreases amyloid‐β production in the central nervous system (2009) (301)
- Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury (2007) (300)
- Deletion of Abca1 Increases Aβ Deposition in the PDAPP Transgenic Mouse Model of Alzheimer Disease* (2005) (298)
- Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo (2013) (293)
- Role of Tissue Plasminogen Activator Receptor LRP in Hippocampal Long-Term Potentiation (2000) (293)
- Loss of TREM2 function increases amyloid seeding but reduces plaque associated ApoE (2018) (291)
- Slow wave sleep disruption increases cerebrospinal fluid amyloid-&bgr; levels (2017) (288)
- Functional connectivity and graph theory in preclinical Alzheimer's disease (2014) (288)
- Decreased cerebrospinal fluid Aβ42 correlates with brain atrophy in cognitively normal elderly (2009) (286)
- Alzheimer disease (2021) (284)
- Nascent Astrocyte Particles Differ from Lipoproteins in CSF (1998) (283)
- The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. (2012) (277)
- Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. (2009) (274)
- Human Apolipoprotein E4 Alters the Amyloid-β 40:42 Ratio and Promotes the Formation of Cerebral Amyloid Angiopathy in an Amyloid Precursor Protein Transgenic Model (2005) (266)
- BDNF Blocks Caspase-3 Activation in Neonatal Hypoxia–Ischemia (2000) (264)
- Exercise and Alzheimer's disease biomarkers in cognitively normal older adults (2010) (263)
- Impaired Synaptic Plasticity and cAMP Response Element-Binding Protein Activation in Ca2+/Calmodulin-Dependent Protein Kinase Type IV/Gr-Deficient Mice (2000) (261)
- Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. (2012) (260)
- Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice (2013) (253)
- TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy (2017) (253)
- Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status (2016) (252)
- A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (252)
- Bcl-xL is an Antiapoptotic Regulator for Postnatal CNS Neurons (1998) (251)
- Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2 (2014) (250)
- Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo (2013) (250)
- Effects of voluntary and forced exercise on plaque deposition, hippocampal volume, and behavior in the Tg2576 mouse model of Alzheimer's disease (2009) (250)
- Active and passive immunotherapy for neurodegenerative disorders. (2008) (248)
- Exercise Engagement as a Moderator of the Effects of APOE Genotype on Amyloid Deposition. (2012) (248)
- Glial contributions to neurodegeneration in tauopathies (2017) (248)
- α2‐Macroglobulin Complexes with and Mediates the Endocytosis of β‐Amyloid Peptide via Cell Surface Low‐Density Lipoprotein Receptor‐Related Protein (1997) (247)
- Amyloid-β Dynamics Correlate with Neurological Status in the Injured Human Brain (2008) (246)
- Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls (2013) (246)
- Epileptogenic effect of hypoxia in the immature rodent brain (1991) (243)
- Human and Murine ApoE Markedly Alters Aβ Metabolism before and after Plaque Formation in a Mouse Model of Alzheimer's Disease (2002) (242)
- Plaque‐associated disruption of CSF and plasma amyloid‐β (Aβ) equilibrium in a mouse model of Alzheimer's disease (2002) (240)
- Antisense Reduction of Tau in Adult Mice Protects against Seizures (2013) (239)
- IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor (2005) (238)
- Controlled Cortical Impact Traumatic Brain Injury in 3xTg-AD Mice Causes Acute Intra-Axonal Amyloid-β Accumulation and Independently Accelerates the Development of Tau Abnormalities (2011) (235)
- Differential Effects of cAMP in Neurons and Astrocytes (1999) (235)
- Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. (2015) (235)
- Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice (2009) (232)
- Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular Aβ Clearance (2009) (230)
- Apolipoprotein E-containing High Density Lipoprotein Promotes Neurite Outgrowth and Is a Ligand for the Low Density Lipoprotein Receptor-related Protein* (1996) (230)
- New insights into the role of TREM2 in Alzheimer’s disease (2018) (227)
- Elucidating the Role of TREM2 in Alzheimer’s Disease (2017) (224)
- Circadian Rest-Activity Pattern Changes in Aging and Preclinical Alzheimer Disease (2018) (223)
- Nitric Oxide Mediates Cerebral Ischemic Tolerance in a Neonatal Rat Model of Hypoxic Preconditioning (1999) (219)
- Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide (2012) (217)
- SIRT1 Promotes the Central Adaptive Response to Diet Restriction through Activation of the Dorsomedial and Lateral Nuclei of the Hypothalamus (2010) (217)
- Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. (2009) (217)
- Multiplexed Immunoassay Panel Identifies Novel CSF Biomarkers for Alzheimer's Disease Diagnosis and Prognosis (2011) (214)
- Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type. (2009) (214)
- Glial Fibrillary Acidic Protein–Apolipoprotein E (apoE) Transgenic Mice: Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE3 and apoE4 Lipoproteins (1998) (212)
- Peripheral neuropathy associated with acquired immunodeficiency syndrome. Prevalence and clinical features from a population-based survey. (1988) (211)
- Unique Lipoproteins Secreted by Primary Astrocytes From Wild Type, apoE (−/−), and Human apoE Transgenic Mice* (1999) (210)
- Lipoproteins in the Central Nervous System (2000) (207)
- Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later (2013) (206)
- Clusterin contributes to caspase-3–independent brain injury following neonatal hypoxia-ischemia (2001) (206)
- Structure-activity relationship of imidazo[1,2-a]pyridines as ligands for detecting beta-amyloid plaques in the brain. (2003) (205)
- Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease (2012) (202)
- Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. (2015) (201)
- Ethanol-induced neuronal apoptosis in vivo requires BAX in the developing mouse brain (2003) (199)
- Increased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers (2013) (198)
- Acute stress increases interstitial fluid amyloid-β via corticotropin-releasing factor and neuronal activity (2007) (197)
- Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1 (2013) (193)
- 1-δ9-Tetrahydrocannabinol: Neurochemical and Behavioral Effects in the Mouse (1969) (193)
- Apolipoprotein E isoform-specific regulation of dendritic spine morphology in apolipoprotein E transgenic mice and Alzheimer's disease patients (2003) (190)
- Electromagnetic controlled cortical impact device for precise, graded experimental traumatic brain injury. (2007) (189)
- Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. (2012) (187)
- Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury (2006) (187)
- Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. (2012) (186)
- Neonatal Mice Lacking Neuronal Nitric Oxide Synthase Are Less Vulnerable to Hypoxic–Ischemic Injury (1996) (186)
- Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model (2019) (185)
- Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. (2005) (185)
- BDNF Protects against Spatial Memory Deficits Following Neonatal Hypoxia-Ischemia (2000) (185)
- Marked age‐dependent neuroprotection by brain‐derived neurotrophic factor against neonatal hypoxic—ischemic brain injury (1997) (179)
- Fluctuations of CSF amyloid-&bgr; levels: Implications for a diagnostic and therapeutic biomarker (2007) (178)
- In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. (1999) (173)
- Assessment of Racial Disparities in Biomarkers for Alzheimer Disease (2019) (173)
- Diffusion tensor imaging detects age-dependent white matter changes in a transgenic mouse model with amyloid deposition (2004) (173)
- Identification and Validation of Novel Cerebrospinal Fluid Biomarkers for Staging Early Alzheimer's Disease (2011) (172)
- Selective, Reversible Caspase-3 Inhibitor Is Neuroprotective and Reveals Distinct Pathways of Cell Death after Neonatal Hypoxic-ischemic Brain Injury* (2002) (172)
- Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis (2011) (172)
- Evaluation of 5-ethynyl-2′-deoxyuridine staining as a sensitive and reliable method for studying cell proliferation in the adult nervous system (2010) (170)
- Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. (2009) (169)
- Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity (2006) (169)
- Chronic optogenetic activation augments aβ pathology in a mouse model of Alzheimer disease. (2015) (169)
- Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease (2009) (169)
- Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease (2014) (168)
- Deciphering Alzheimer disease. (2012) (168)
- Reduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease (2019) (168)
- Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic mice (2001) (167)
- Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging (2018) (166)
- Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology. (2011) (164)
- Behavioral Phenotyping of GFAP-ApoE3 and -ApoE4 Transgenic Mice: ApoE4 Mice Show Profound Working Memory Impairments in the Absence of Alzheimer's-like Neuropathology (2001) (164)
- Bidirectional relationship between sleep and Alzheimer’s disease: role of amyloid, tau, and other factors (2019) (163)
- Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease (2018) (163)
- Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes (2016) (163)
- Bidirectional Relationship between Functional Connectivity and Amyloid-β Deposition in Mouse Brain (2012) (161)
- Maternal Dietary Supplementation with Pomegranate Juice Is Neuroprotective in an Animal Model of Neonatal Hypoxic-Ischemic Brain Injury (2005) (161)
- Hyperglycemia modulates extracellular amyloid-β concentrations and neuronal activity in vivo. (2015) (159)
- The relationship between cerebrospinal fluid markers of Alzheimer pathology and positron emission tomography tau imaging. (2016) (159)
- Critical Role of Astroglial Apolipoprotein E and Liver X Receptor-α Expression for Microglial Aβ Phagocytosis (2011) (158)
- CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease (2009) (158)
- ApoE facilitates the microglial response to amyloid plaque pathology (2018) (158)
- Pomegranate Polyphenols and Resveratrol Protect the Neonatal Brain against Hypoxic-Ischemic Injury (2007) (157)
- Hyperthermia-induced seizures in the rat pup: a model for febrile convulsions in children. (1981) (157)
- Reperfusion Differentially Induces Caspase-3 Activation in Ischemic Core and Penumbra After Stroke in Immature Brain (2003) (153)
- Nerve growth factor protects the neonatal brain against hypoxic–ischemic injury (1996) (153)
- Comment on “ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models” (2013) (153)
- Rapid Microglial Response Around Amyloid Pathology after Systemic Anti-Aβ Antibody Administration in PDAPP Mice (2008) (152)
- Alzheimer disease in 2020. (2012) (151)
- The Choroid Plexus and Cerebrospinal Fluid: Emerging Roles in Development, Disease, and Therapy (2013) (151)
- Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury. (2012) (150)
- Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. (2007) (150)
- Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry. (2006) (150)
- Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation (2016) (149)
- Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. (2016) (149)
- Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of Aβ Uptake and Degradation by Astrocytes* (2012) (148)
- Anti-tau antibody reduces insoluble tau and decreases brain atrophy (2015) (148)
- Apolipoprotein E Markedly Facilitates Age-Dependent Cerebral Amyloid Angiopathy and Spontaneous Hemorrhage in Amyloid Precursor Protein Transgenic Mice (2003) (147)
- New-onset seizures associated with human immunodeficiency virus infection: causation and clinical features in 100 cases. (1989) (143)
- Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition (2017) (142)
- A Role for TrkA during Maturation of Striatal and Basal Forebrain Cholinergic Neurons In Vivo (1997) (140)
- Visinin‐like protein‐1: Diagnostic and prognostic biomarker in Alzheimer disease (2011) (140)
- The Low Density Lipoprotein Receptor Regulates the Level of Central Nervous System Human and Murine Apolipoprotein E but Does Not Modify Amyloid Plaque Pathology in PDAPP Mice* (2005) (140)
- Changes in insulin and insulin signaling in Alzheimer’s disease: cause or consequence? (2016) (139)
- TREM2 function impedes tau seeding in neuritic plaques (2019) (139)
- Apolipoprotein E and Low Density Lipoprotein Receptor-related Protein Facilitate Intraneuronal Aβ42 Accumulation in Amyloid Model Mice* (2006) (139)
- The utility of intraindividual variability in selective attention tasks as an early marker for Alzheimer's disease. (2009) (135)
- Evidence for peripheral clearance of cerebral Aβ protein following chronic, active Aβ immunization in PSAPP mice (2003) (133)
- Amyloid-ss Dynamics Correlate with Neurological Status in the Injured Human Brain (2009) (133)
- Lysosomal Sorting of Amyloid-β by the SORLA Receptor Is Impaired by a Familial Alzheimer’s Disease Mutation (2014) (132)
- Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis (2012) (131)
- Cerebrovascular Dysfunction in Amyloid Precursor Protein Transgenic Mice: Contribution of Soluble and Insoluble Amyloid-β Peptide, Partial Restoration via γ-Secretase Inhibition (2008) (131)
- BAX Contributes to Apoptotic-Like Death Following Neonatal Hypoxia-Ischemia: Evidence for Distinct Apoptosis Pathways (2001) (131)
- Age and amyloid effects on human central nervous system amyloid‐beta kinetics (2015) (130)
- Increased soluble amyloid-beta peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. (2004) (130)
- Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins (2017) (129)
- Treatment with an Amyloid-β Antibody Ameliorates Plaque Load, Learning Deficits, and Hippocampal Long-Term Potentiation in a Mouse Model of Alzheimer's Disease (2005) (129)
- Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism (2018) (129)
- SNPs Associated with Cerebrospinal Fluid Phospho-Tau Levels Influence Rate of Decline in Alzheimer's Disease (2010) (128)
- Clearance of amyloid β-peptide from brain: transport or metabolism? (2000) (126)
- A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice (2004) (126)
- Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging (2005) (126)
- Apolipoprotein E4 Influences Amyloid Deposition But Not Cell Loss after Traumatic Brain Injury in a Mouse Model of Alzheimer's Disease (2002) (126)
- Evidence for Normal Aging of the Septo-Hippocampal Cholinergic System in apoE (−/−) Mice but Impaired Clearance of Axonal Degeneration Products Following Injury (1998) (124)
- Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex (2007) (121)
- Apolipoprotein E, amyloid, and Alzheimer disease. (2002) (120)
- In vivo effects of apoE and clusterin on amyloid-β metabolism and neuropathology (2007) (119)
- Novel Role for Apolipoprotein E in the Central Nervous System (2003) (119)
- Genome-wide association study identifies four novel loci associated with Alzheimer’s endophenotypes and disease modifiers (2017) (117)
- Role of caspase-3 in ethanol-induced developmental neurodegeneration (2005) (117)
- Transgenic mouse brain histopathology resembles early Alzheimer's disease (1994) (116)
- Plaque-associated disruption of CSF and plasma amyloid-beta (Abeta) equilibrium in a mouse model of Alzheimer's disease. (2002) (116)
- Missense variant in TREML2 protects against Alzheimer's disease (2014) (115)
- Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype (2000) (115)
- The sleep-wake cycle and Alzheimer's disease: what do we know? (2014) (115)
- Genome-Wide Association Study of CSF Levels of 59 Alzheimer's Disease Candidate Proteins: Significant Associations with Proteins Involved in Amyloid Processing and Inflammation (2014) (114)
- Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis (2012) (114)
- Maturation of resistance to lead encephalopathy: cellular and subcellular mechanisms. (1984) (113)
- Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. (2011) (113)
- Contribution of reactive oxygen species to cerebral amyloid angiopathy, vasomotor dysfunction, and microhemorrhage in aged Tg2576 mice (2015) (112)
- Biomarkers of Alzheimer's disease (2009) (112)
- TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis (2020) (111)
- Energy‐dependent volume regulation in primary cultured cerebral astrocytes (1986) (111)
- Plasma Cortisol and Progression of Dementia in DAT Subjects (2006) (110)
- Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-β clearance and aggregation in Alzheimer’s disease (2016) (110)
- In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis (2013) (110)
- Dynamic Analysis of Amyloid β-Protein in Behaving Mice Reveals Opposing Changes in ISF versus Parenchymal Aβ during Age-Related Plaque Formation (2011) (110)
- Multi‐component apparent diffusion coefficients in human brain: Relationship to spin‐lattice relaxation (2000) (109)
- Anti-ApoE Antibody Given after Plaque Onset Decreases Aβ Accumulation and Improves Brain Function in a Mouse Model of Aβ Amyloidosis (2014) (108)
- Tau: From research to clinical development (2016) (108)
- Obstructive sleep apnea decreases central nervous system–derived proteins in the cerebrospinal fluid (2016) (108)
- Sleep in Alzheimer's Disease–Beyond Amyloid (2016) (108)
- Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia (2003) (107)
- Matrix metalloproteinase–9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy (2003) (107)
- A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain (2019) (106)
- Functional connectivity in autosomal dominant and late-onset Alzheimer disease. (2014) (106)
- Role of apoE/Aβ interactions in the pathogenesis of Alzheimer’s disease and cerebral amyloid angiopathy (2001) (106)
- Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort (2015) (105)
- Nerve growth factor and the neurotrophic factor hypothesis (1996) (105)
- A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer's disease (2016) (105)
- CSF biomarkers for Alzheimer's disease: current utility and potential future use (2011) (105)
- Regulation of amyloid-β dynamics and pathology by the circadian clock (2018) (104)
- The Low‐Density Lipoprotein Receptor‐Related Protein, a Multifunctional Apolipoprotein E Receptor, Modulates Hippocampal Neurite Development (1997) (104)
- Age-Dependent Effects of apoE Reduction Using Antisense Oligonucleotides in a Model of β-amyloidosis (2017) (104)
- Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy (2021) (103)
- Dural lymphatics regulate clearance of extracellular tau from the CNS (2019) (103)
- Tau PET in autosomal dominant Alzheimer’s disease: relationship with cognition, dementia and other biomarkers (2019) (103)
- β‐Secretase inhibitor GRL‐8234 rescues age‐related cognitive decline in APP transgenic mice (2011) (103)
- ApoE4 upregulates the activity of mitochondria‐associated ER membranes (2015) (101)
- The Low Density Lipoprotein Receptor-related Protein 1 Mediates Uptake of Amyloid β Peptides in an in Vitro Model of the Blood-Brain Barrier Cells* (2008) (101)
- Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer’s disease (2018) (101)
- Translational profiling of hypocretin neurons identifies candidate molecules for sleep regulation. (2013) (100)
- CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease (2012) (100)
- Phospholipid dysregulation contributes to ApoE4-associated cognitive deficits in Alzheimer’s disease pathogenesis (2015) (98)
- Reduction of Cytochrome aa3 Measured by Near-Infrared Spectroscopy Predicts Cerebral Energy Loss in Hypoxic Piglets (1995) (98)
- Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol (2020) (96)
- 'Hot spots' of creatine kinase localization in brain: cerebellum, hippocampus and choroid plexus. (1996) (96)
- Cell Death Mechanism and Protective Effect of Erythropoietin after Focal Ischemia in the Whisker-Barrel Cortex of Neonatal Rats (2006) (96)
- TREM2 Function in Alzheimer's Disease and Neurodegeneration. (2016) (96)
- microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) (95)
- Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies. (2017) (94)
- Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition (2008) (94)
- Effect of Different Anti-Aβ Antibodies on Aβ Fibrillogenesis as Assessed by Atomic Force Microscopy (2004) (93)
- Relationship of dementia screening tests with biomarkers of Alzheimer's disease. (2010) (93)
- Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. (1997) (92)
- SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. (2013) (92)
- Machine learning for comprehensive forecasting of Alzheimer’s Disease progression (2018) (92)
- The Binding of Apolipoprotein E to Oligomers and Fibrils of Amyloid-β Alters the Kinetics of Amyloid Aggregation (2014) (92)
- Dietary salt promotes cognitive impairment through tau phosphorylation (2018) (92)
- Comparison of a single‐channel EEG sleep study to polysomnography (2016) (91)
- Alzheimer's Disease–Related Dementias Summit 2016: National research priorities (2017) (91)
- Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation (2018) (91)
- Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. (2001) (91)
- Polygenic risk score of sporadic late-onset Alzheimer's disease reveals a shared architecture with the familial and early-onset forms (2018) (89)
- Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease (2016) (89)
- NIA-AA staging of preclinical Alzheimer disease: discordance and concordance of CSF and imaging biomarkers (2016) (88)
- Longitudinal β-Amyloid Deposition and Hippocampal Volume in Preclinical Alzheimer Disease and Suspected Non-Alzheimer Disease Pathophysiology. (2016) (88)
- Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia (2021) (88)
- In vivo effects of ApoE and clusterin on amyloid-beta metabolism and neuropathology. (2004) (88)
- Endogenous FGF-2 Is Important for Cholinergic Sprouting in the Denervated Hippocampus (1997) (87)
- Comparative Proteomic Analysis of Intra- and Interindividual Variation in Human Cerebrospinal Fluid*S (2005) (87)
- Alzheimer’s disease risk variants show association with cerebrospinal fluid amyloid beta (2009) (87)
- Cerebrospinal fluid Aβ42, phosphorylated Tau181, and resting-state functional connectivity. (2013) (87)
- Extreme cerebrospinal fluid amyloid β levels identify family with late‐onset Alzheimer's disease presenilin 1 mutation (2007) (86)
- Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-β (2005) (86)
- Apolipoprotein E: Structural Insights and Links to Alzheimer Disease Pathogenesis (2020) (85)
- Distinct Therapeutic Mechanisms of Tau Antibodies (2015) (85)
- Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. (2020) (84)
- Caffeic acid phenethyl ester prevents neonatal hypoxic-ischaemic brain injury. (2004) (84)
- Trisomy of human chromosome 21 enhances amyloid-β deposition independently of an extra copy of APP (2018) (83)
- Mood Changes in Cognitively Normal Older Adults are Linked to Alzheimer Disease Biomarker Levels. (2016) (82)
- Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. (2015) (82)
- Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. (2005) (80)
- Astrocyte lipoproteins, effects of apoE on neuronal function, and role of apoE in amyloid‐β deposition in vivo (2000) (79)
- Analysis of IFT74 as a candidate gene for chromosome 9p-linked ALS-FTD (2006) (79)
- In situ atomic force microscopy study of Alzheimer's beta-amyloid peptide on different substrates: new insights into mechanism of beta-sheet formation. (1999) (79)
- Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. (2012) (79)
- Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) (78)
- APOE genotype regulates pathology and disease progression in synucleinopathy (2020) (78)
- Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms (2007) (77)
- Amyloid-β and Tau at the Crossroads of Alzheimer's Disease. (2019) (77)
- Mapping the Road Forward in Alzheimer’s Disease (2011) (77)
- Creatine Increases Survival and Suppresses Seizures in the Hypoxic Immature Rat (1998) (76)
- Intercellular Spread of Protein Aggregates in Neurodegenerative Disease. (2018) (76)
- Fine Mapping of Genetic Variants in BIN1, CLU, CR1 and PICALM for Association with Cerebrospinal Fluid Biomarkers for Alzheimer's Disease (2011) (75)
- Non-coding variability at the APOE locus contributes to the Alzheimer’s risk (2019) (74)
- Impaired Autophagy in APOE4 Astrocytes. (2016) (74)
- Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of Tuberous Sclerosis Complex (2010) (72)
- Stable isotope labeling tandem mass spectrometry (SILT) to quantify protein production and clearance rates (2007) (71)
- Longitudinal brain imaging in preclinical Alzheimer disease: impact of APOE &egr;4 genotype (2018) (71)
- Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy (2017) (71)
- Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. (2013) (69)
- White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimer’s disease (2018) (68)
- Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age‐related neurodegeneration (1993) (68)
- PDAPP; YFP double transgenic mice: A tool to study amyloid‐β associated changes in axonal, dendritic, and synaptic structures (2003) (67)
- Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice. (2003) (67)
- 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. (2012) (67)
- A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis (2021) (66)
- Caspases: A treatment target for neurodegenerative disease? (1997) (66)
- Role of apoe/Abeta interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. (2001) (65)
- Nerve Growth Factor Induces Rapid Increases in Functional Cell Surface Low Density Lipoprotein Receptor-related Protein* (1998) (65)
- In vivo MRI analysis of an inflammatory injury in the developing brain (2010) (64)
- Neuropathology for the Neuroradiologist: Plaques and Tangles (2008) (64)
- High‐affinity interactions and signal transduction between Aβ oligomers and TREM2 (2018) (64)
- Opposing Synaptic Regulation of Amyloid-β Metabolism by NMDA Receptors In Vivo (2011) (64)
- ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis. (2004) (63)
- Apolipoprotein E mediates sulfatide depletion in animal models of Alzheimer's disease (2010) (62)
- A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. (2004) (62)
- Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease (2007) (62)
- Clearance of amyloid beta-peptide from brain: transport or metabolism? (2000) (62)
- Biomarkers in translational research of Alzheimer’s Disease (2010) (62)
- The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers (2013) (62)
- Soluble amyloid-β, effect on cerebral arteriolar regulation and vascular cells (2010) (62)
- Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease (2019) (61)
- Lead toxicity in primary cultured cerebral astrocytes and cerebellar granular neurons. (1987) (60)
- Analysis of in vivo turnover of tau in a mouse model of tauopathy (2015) (60)
- BDNF Val66Met moderates memory impairment, hippocampal function and tau in preclinical autosomal dominant Alzheimer's disease. (2016) (59)
- Role of nerve growth factor in experimental autoimmune encephalomyelitis (2001) (58)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (56)
- Tau and Ab imaging, CSF measures, and cognition in Alzheimer’s disease (2016) (56)
- The action of anesthetics on excitable membranes: a quantum-chemical analysis. (1965) (56)
- NOS induction by NGF in basal forebrain cholinergic neurones: evidence for regulation of brain NOS by a neurotrophin (1994) (56)
- Improving CSF biomarker accuracy in predicting prevalent and incident Alzheimer disease (2011) (56)
- Obstructive sleep apnea treatment, slow wave activity, and amyloid‐β (2019) (56)
- Toward a multifactorial model of Alzheimer disease (2012) (55)
- Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell death (2011) (55)
- Traumatic brain injury reduces soluble extracellular amyloid-β in mice: A methodologically novel combined microdialysis-controlled cortical impact study (2010) (55)
- 7 – Nerve Growth Factor: Actions in the Peripheral and Central Nervous Systems (1993) (54)
- Mouse model of neurodegeneration: atrophy of basal forebrain cholinergic neurons in trisomy 16 transplants. (1992) (54)
- Gut Microbiota: From the Forgotten Organ to a Potential Key Player in the Pathology of Alzheimer’s Disease (2019) (53)
- Functional maturation of creatine kinase in rat brain. (1993) (53)
- TFEB regulates lysosomal exocytosis of tau and its loss of function exacerbates tau pathology and spreading (2020) (52)
- APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function (2021) (52)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (52)
- Differences in the Abeta40/Abeta42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. (2000) (52)
- Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model (2019) (51)
- Cholesterol and matrisome pathways dysregulated in astrocytes and microglia (2022) (50)
- Cellular catabolism of lipid poor apolipoprotein E via cell surface LDL receptor-related protein. (2002) (50)
- The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain (2012) (50)
- Respiration in rat cerebral astrocytes from primary culture (1980) (50)
- Caspase-3 deficiency during development increases vulnerability to hypoxic–ischemic injury through caspase-3-independent pathways (2006) (50)
- Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. (2005) (49)
- Role of family history for Alzheimer biomarker abnormalities in the adult children study. (2011) (49)
- Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease (2017) (49)
- Aβ immunization and anti-Aβ antibodies: potential therapies for the prevention and treatment of Alzheimer’s disease (2002) (49)
- Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. (2010) (49)
- Effect of cephaloridine on respiration by renal cortical mitochondria. (1979) (48)
- Quantitative Label-Free Proteomics for Discovery of Biomarkers in Cerebrospinal Fluid: Assessment of Technical and Inter-Individual Variation (2013) (48)
- Cognitively unimpaired HIV-positive subjects do not have increased 11C-PiB (2010) (48)
- Amyloid-beta dynamics in the injured human brain (2009) (47)
- Activated microglia mitigate Aβ-associated tau seeding and spreading (2021) (47)
- Early Effects of Inorganic Lead on Immature Rat Brain Mitochondrial Respiration (1976) (47)
- C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation (2021) (46)
- A randomized controlled study to evaluate the effect of bexarotene on amyloid-β and apolipoprotein E metabolism in healthy subjects (2016) (46)
- In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) (46)
- Altered sleep and EEG power in the P301S Tau transgenic mouse model (2017) (46)
- Supply and demand analysis of the current and future US neurology workforce (2014) (45)
- Altered brain phosphocreatine and ATP regulation when mitochondrial creatine kinase is absent (2001) (45)
- Clearance of interstitial fluid (ISF) and CSF (CLIC) group—part of Vascular Professional Interest Area (PIA) (2020) (45)
- A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin (2016) (45)
- Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models (2015) (44)
- Alternative processing of γ‐secretase substrates in common forms of mild cognitive impairment and alzheimer's disease: Evidence for γ‐secretase dysfunction (2011) (44)
- Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models (2016) (44)
- Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo (2009) (44)
- Alzheimer's disease: Moving towards a vaccine (2008) (43)
- Relationship between Stroop performance and resting state functional connectivity in cognitively normal older adults. (2013) (43)
- Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) (43)
- The Effects of Peripheral and Central High Insulin on Brain Insulin Signaling and Amyloid-β in Young and Old APP/PS1 Mice (2016) (42)
- How amyloid, sleep and memory connect (2015) (42)
- Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 years (2018) (42)
- Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma* (2016) (41)
- Calcium-Stimulated Adenylyl Cyclases Modulate Ethanol-Induced Neurodegeneration in the Neonatal Brain (2005) (41)
- Critical issues for successful immunotherapy in Alzheimer's disease: development of biomarkers and methods for early detection and intervention. (2009) (41)
- Control of astrocyte volume by intracellular and extracellular Ca2+ (1990) (41)
- ApoE Cascade Hypothesis in the pathogenesis of Alzheimer’s disease and related dementias (2022) (41)
- Aging, gender and APOE isotype modulate metabolism of Alzheimer's Aβ peptides and F2‐isoprostanes in the absence of detectable amyloid deposits (2004) (40)
- Cerebral Oxygenation Measured by Near Infrared Spectroscopy during Cardiopulmonary Bypass and Deep Hypothermic Circulatory Arrest in Piglets (1996) (40)
- Quantitative analysis of amyloid-beta peptides in cerebrospinal fluid using immunoprecipitation and MALDI-Tof mass spectrometry. (2007) (40)
- Lack of BACE1 S-palmitoylation reduces amyloid burden and mitigates memory deficits in transgenic mouse models of Alzheimer’s disease (2017) (40)
- Diffusion characteristics associated with neuronal injury and glial activation following hypoxia‐ischemia in the immature brain (2011) (39)
- AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy (2017) (39)
- Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. (2004) (39)
- Maturational increase in mouse brain creatine kinase reaction rates shown by phosphorus magnetic resonance. (1991) (39)
- Cerebrospinal fluid biomarkers, education, brain volume, and future cognition. (2011) (39)
- In vivo brain phosphocreatine and ATP regulation in mice fed a creatine analog. (1997) (39)
- Potential role of apoE in structural plasticity in the nervous system; implications for disorders of the central nervous system. (1998) (38)
- Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms (2021) (38)
- Preclinical Alzheimer's disease and longitudinal driving decline (2016) (38)
- In Vivo Development of Brain Phosphocreatine in Normal and Creatine‐Treated Rabbit Pups (1999) (38)
- Amyloid- b Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle (2009) (38)
- Antibody Therapeutics Targeting Aβ and Tau. (2017) (38)
- New insights into the role of TREM 2 in Alzheimer ’ s disease (2019) (38)
- Brain creatine phosphate and creatine kinase in mice fed an analogue of creatine (1989) (37)
- Molecular studies in Alzheimer's disease. (1991) (37)
- Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study (2015) (36)
- In situ AFM studies of astrocyte-secreted apolipoprotein E- and J-containing lipoproteins. (2004) (36)
- Neurotrophic factors and neurologic disease. (1994) (36)
- Behavioral and transcriptomic analysis of Trem2-null mice: not all knockout mice are created equal (2017) (35)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (35)
- Sleep deprivation differentially affects dopamine receptor subtypes in mouse striatum (2011) (34)
- Cholesterol and matrisome pathways dysregulated in human APOE ε4 glia (2019) (34)
- Task-evoked fMRI changes in attention networks are associated with preclinical Alzheimer’s disease biomarkers (2015) (33)
- Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model (2015) (33)
- 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) (33)
- Oxidative phosphorylation in immature rat brain mitochondria. (1973) (33)
- High affinity interactions and signal transduction between Aβ oligomers and TREM2 (2018) (32)
- Amyloid-β(1-15/16) as a marker for γ-secretase inhibition in Alzheimer's disease. (2012) (31)
- CSF biomarkers of Alzheimer disease (2013) (31)
- Glass Microelectrodes: the Origin and Elimination of Tip Potentials (1966) (31)
- Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure (2021) (31)
- Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta). (2004) (30)
- The microbiome: A target for Alzheimer disease? (2019) (30)
- Cortical Binding of Pittsburgh Compound B, an Endophenotype for Genetic Studies of Alzheimer's Disease (2010) (30)
- The search for antecedent biomarkers of Alzheimer's disease. (2006) (29)
- 1-delta9-tetrahydrocannabinol: neurochemical and behavioral effects in the mouse. (1969) (29)
- Phosphocreatine and ATP regulation in the hypoxic developing rat brain. (1995) (29)
- Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study (2022) (29)
- Amyloid Imaging, Cerebrospinal Fluid Biomarkers Predict Driving Performance Among Cognitively Normal Individuals (2017) (29)
- Chronic hexosaminidase A and B deficiency (1977) (29)
- Role of apoE/Aβ interactions in Alzheimer's disease: insights from transgenic mouse models (2002) (29)
- Emergence of a seizure phenotype in aged apolipoprotein epsilon 4 targeted replacement mice (2012) (29)
- Cerebrospinal Fluid Proteins Predict Longitudinal Hippocampal Degeneration in Early-stage Dementia of the Alzheimer Type (2012) (29)
- High density lipoprotein decreases β‐amyloid toxicity in cortical cell culture (1997) (29)
- Progress Update: Fluid and Imaging Biomarkers in Alzheimer’s Disease (2014) (29)
- Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
- Profound, reversible energy loss in the hypoxic immature rat brain. (1993) (28)
- Functional insights from biophysical study of TREM2 interactions with ApoE and Aβ1-42 (2020) (28)
- Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease. (2021) (28)
- Respiration and cell volume of primary cultured cerebral astrocytes in media of various osmolarities (1982) (28)
- Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits (2016) (28)
- Cerebrospinal fluid biomarkers of Alzheimer's disease. (2010) (27)
- Amyloid β and Alzheimer disease therapeutics: the devil may be in the details (2003) (27)
- Alzheimer disease biomarkers, attentional control, and semantic memory retrieval: Synergistic and mediational effects of biomarkers on a sensitive cognitive measure in non-demented older adults. (2015) (27)
- Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. (2002) (27)
- Cerebrospinal Fluid Levels of Amyloid Precursor Protein Are Associated with Ventricular Size in Post-Hemorrhagic Hydrocephalus of Prematurity (2015) (27)
- Evidence that p38 Mitogen-Activated Protein Kinase Contributes to Neonatal Hypoxic-Ischemic Brain Injury (2003) (26)
- Alzheimer’s Aβ vaccination of rhesus monkeys (Macaca mulatta) (2004) (26)
- No effect of apolipoprotein E on neuronal cell death due to excitotoxic and apoptotic agents in vitro and neonatal hypoxic ischaemia in vivo (2000) (26)
- Efficacy and toxicity of clioquinol treatment and A-beta42 inoculation in the APP/PSI mouse model of Alzheimer's disease. (2013) (25)
- Role of biomarkers in studies of presymptomatic Alzheimer’s disease (2005) (25)
- Minocycline Reduces Spontaneous Hemorrhage in Mouse Models of Cerebral Amyloid Angiopathy (2015) (25)
- Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease (2021) (25)
- The modulating effect of mechanical changes in lipid bilayers caused by apoE-containing lipoproteins on Aβ induced membrane disruption. (2011) (25)
- RESPIRATION IN IMMATURE RAT BRAIN MITOCHONDRIA (1975) (25)
- Relative phosphocreatine and nucleoside triphosphate concentrations in cerebral gray and white matter measured in vivo by 31P nuclear magnetic resonance (1996) (25)
- Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling (2012) (24)
- EFFECTS OF OSMOLAR CHANGES ON ISOLATED MITOCHONDRIA OF BRAIN AND LIVER (1978) (24)
- Early Diffusion-Weighted MRI as a Predictor of Caspase-3 Activation After Hypoxic–Ischemic Insult in Neonatal Rodents (2008) (24)
- Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers (2018) (24)
- Development of Resistance to Lead Encephalopathy During Maturation in the Rat Pup (1982) (24)
- Expectations and challenges in the therapeutic use of neurotrophic factors (2006) (23)
- Cerebral Amyloid Angiopathy Increases Susceptibility to Infarction After Focal Cerebral Ischemia in Tg2576 Mice (2014) (23)
- In vivo phosphocreatine and ATP in piglet cerebral gray and white matter during seizures (1998) (23)
- Diurnal oscillation of CSF Aβ and other AD biomarkers (2017) (22)
- APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease. (2022) (22)
- Bcl-x Pre-mRNA Splicing Regulates Brain Injury after Neonatal Hypoxia-Ischemia (2012) (22)
- Targeting tauopathy with engineered tau-degrading intrabodies (2019) (22)
- The informed road map to prevention of Alzheimer Disease: A call to arms (2021) (22)
- Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis (2022) (22)
- Use of YFP to study amyloid-β associated neurite alterations in live brain slices (2003) (22)
- Parenchymal border macrophages regulate the flow dynamics of the cerebrospinal fluid (2022) (22)
- TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways (2022) (22)
- RARE imaging of PCr in human forearm muscles (1997) (22)
- Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis (2014) (21)
- “Alzheimer's disease” is neither “Alzheimer's clinical syndrome” nor “dementia” (2019) (21)
- 18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery (2018) (21)
- AMPA-ergic regulation of amyloid-β levels in an Alzheimer’s disease mouse model (2018) (21)
- Glial Fibrillary Acidic Protein – Apolipoprotein E ( apoE ) Transgenic Mice : Astrocyte-Specific Expression and Differing Biological Effects of Astrocyte-Secreted apoE 3 and apoE 4 Lipoproteins (1998) (21)
- Lumbar Cerebrospinal Fluid Biomarkers of Posthemorrhagic Hydrocephalus of Prematurity: Amyloid Precursor Protein, Soluble Amyloid Precursor Protein &agr;, and L1 Cell Adhesion Molecule (2016) (21)
- Brain creatine kinase reaction rates and reactant concentrations during seizures in developing rats (1997) (21)
- A multifaceted intervention to reduce rates of catheter-associated urinary tract infections in a resource-limited setting. (2014) (20)
- Case records of the Massachusetts General Hospital. Case 36-2005. A 61-year-old woman with seizure, disturbed gait, and altered mental status. (2005) (20)
- Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease (2019) (20)
- Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal brain injury (2009) (20)
- APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) (20)
- Maturation of Potassium‐Stimulated Respiration in Rat Cerebral Cortical Slices (1982) (19)
- Preliminary characterization of the central nervous system in partial trisomy 16 mice. (1995) (19)
- Ultrastructural studies in APP/PS1 mice expressing human ApoE isoforms: implications for Alzheimer's disease. (2012) (19)
- Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta). (2004) (19)
- A micro-method for the study of oxidative phosphorylation. (1971) (19)
- The pathogenesis of lead encephalopathy (1980) (19)
- Neurotrophin signalling in the nervous system (1993) (19)
- Functional insights from biophysical study of TREM2 interactions with apoE and Aβ1‐42 (2020) (19)
- The Bad Seed in Alzheimer’s Disease (2005) (19)
- African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants (2021) (18)
- Prion-Like Behavior of Amyloid-β (2010) (18)
- Multi‐echo 31P spectroscopic imaging of ATP: A scan time reduction strategy (1997) (18)
- Fluid Biomarkers for Alzheimer’s Disease (2013) (18)
- Differential metabolism of ApoE isoforms in plasma and CSF (2003) (18)
- Medicine. Prion-like behavior of amyloid-beta. (2010) (18)
- Phosphocreatine and creatine kinase in piglet cerebral gray and white matter in situ. (1996) (18)
- Translocator protein in late stage Alzheimer’s disease and Dementia with Lewy bodies brains (2019) (17)
- Autistic spectrum disorders and mitochondrial encephalopathies (2008) (17)
- Microsomal Cytochromes in the Immature and Adult Rat Brain (1980) (17)
- Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer’s Disease Pathology (2015) (17)
- Astrocytic α2-Na+/K+ ATPase inhibition suppresses astrocyte reactivity and reduces neurodegeneration in a tauopathy mouse model (2022) (17)
- In vitro effects of inorganic lead on isolated rat brain mitochondrial respiration (1978) (17)
- Cerebrospinal fluid biomarkers of infantile congenital hydrocephalus (2017) (17)
- Creatine Kinase-Catalyzed Reaction Rate in the Cyanide-Poisoned Mouse Brain (1993) (17)
- Sigma-2 receptor binding is decreased in female, but not male, APP/PS1 mice. (2015) (16)
- Senescent glia spell trouble in Alzheimer’s disease (2019) (16)
- Role of apoE/Abeta interactions in Alzheimer's disease: insights from transgenic mouse models. (2002) (16)
- Brain Creatine Kinase and Creatine Transporter Proteins in Normal and Creatine-Treated Rabbit Pups (2000) (16)
- A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans (2016) (16)
- Role of A β Transport and Clearance in the Pathogenesis and Treatment of Alzheimer’s Disease (2007) (16)
- Multiecho Approaches to Spectroscopic Imaging of the Brain a (1997) (16)
- Alzheimer disease: advances in pathogenesis, diagnosis, and therapy. (2011) (16)
- Nmnat1 protects neuronal function without altering phospho‐tau pathology in a mouse model of tauopathy (2016) (16)
- 2017 NIA-AA RESEARCH FRAMEWORK TO INVESTIGATE THE ALZHEIMER’S DISEASE CONTINUUM (2017) (15)
- Octanoic Acid Inhibits Astrocyte Volume Control: Implications for Cerebral Edema in Reye's Syndrome (1989) (15)
- Ceramide Is Responsible for the Failure of Compensatory Nerve Sprouting in Apolipoprotein E Knock-Out Mice (2008) (15)
- Missense variant in TREML 2 protects against Alzheimer ’ s Disease (2013) (15)
- Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment (2022) (15)
- Amyloid-beta immunotherapies in mice and men. (2006) (14)
- Respiration in Primary Cultured Cerebellar Granule Neurons and Cerebral Cortical Neurons (1984) (14)
- Brain ATP Metabolism in Hypoxia Resistant Mice Fed Guanidinopropionic Acid (1998) (14)
- Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model (2021) (14)
- Astrocyte volume regulation and ATP and phosphocreatine concentrations after exposure to salicylate, ammonium, and fatty acids (1992) (14)
- The biology of Alzheimer disease (2012) (14)
- Distinct Therapeutic Mechanisms of Tau Antibodies PROMOTING MICROGLIAL CLEARANCE VERSUS BLOCKING NEURONAL UPTAKE * (2015) (14)
- Pretreatment with Human Chorionic Gonadotropin Protects the Neonatal Brain against the Effects of Hypoxic-Ischemic Injury (2017) (14)
- The Pathogenesis of Lead Encephalopathy in the Rat Pup: Effects of Maternal PbCO3 Feedings from Birth (1978) (13)
- Amyloid-β Immunotherapies in Mice and Men (2006) (13)
- Absence of effects of lead feedings and growth-retardation on mitochondrial and microsomal cytochromes in the developing brain. (1981) (13)
- The molecular genetics of Down syndrome. (1992) (13)
- Cerebral oxygenation and blood flow in infant and young adult rats. (1989) (13)
- Aducanumab for Alzheimer disease: the amyloid hypothesis moves from bench to bedside. (2021) (13)
- Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40 (2016) (13)
- Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer’s disease subjects (2012) (13)
- Amyloid beta and Alzheimer disease therapeutics: the devil may be in the details. (2003) (13)
- Effects of growth hormone–releasing hormone on sleep and brain interstitial fluid amyloid-β in an APP transgenic mouse model (2015) (13)
- Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET (2021) (12)
- Immunization therapy for Alzheimer disease? (2005) (12)
- Brain creatine kinases and phosphocreatine: an update. (1996) (12)
- Erratum: National Institute of Neurological Disorders and Stroke-Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards (Stroke (2006) 37, 9, (2220-2241)) (2007) (12)
- ApoE isoform– and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy (2023) (11)
- Expression of Human Apolipoprotein E Downregulates Amyloid Precursor Protein-Induced Ischemic Susceptibility (2002) (11)
- Shark heart mitochondria: effects of external osmolality on respiration. (1979) (11)
- Apolipoprotein E4 impairs the response of neurodegenerative retinal microglia and prevents neuronal loss in glaucoma. (2022) (11)
- ApoE4 reduction with ASOs decreases neurodegeneration in a tauopathy model. (2021) (10)
- Brain cellular and mitochondrial respiration in media of altered pH (1987) (10)
- Effects of triiodothyronine on oxidative phosphorylation in immature rat brain mitochondria (1977) (10)
- RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO-CONTROLLED STUDY OF ABBV-8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY ALZHEIMER’S DISEASE (2017) (10)
- Expression of neuronal-NOS in developing basal forebrain cholinergic neurons: Regulation by NGF (1996) (10)
- Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report. (2017) (10)
- Scanning electron microscopic study of lead effects on cerebral astrocytes in primary culture. (1982) (10)
- Effect of Trypsin on Resting Potential of Frog Muscle (1965) (10)
- Dementia is not synonymous with Alzheimer’s disease (2019) (10)
- Aβ conformational change is central to Alzheimer’s disease (2002) (10)
- Correspondence of CSF biomarkers measured by Lumipulse assays with amyloid PET (2021) (9)
- Apolipoprotein E levels and Alzheimer risk (2015) (9)
- FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2020) (9)
- Biomarkers will revolutionize the way we diagnose and treat Alzheimer's disease. (2010) (9)
- Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease (2021) (9)
- Driving cessation over a 24-year period: Dementia severity and cerebrospinal fluid biomarkers (2018) (9)
- P4-358 In vitro and in vivo characterization of beta-amyloid antibodies binding to cerebral amyloid angiopathy (CAA) and the selective exacerbation of CAA-associated microhemorrhage (2004) (9)
- In Search of an Identity for Amyloid Plaques (2018) (9)
- Chronic TREM2 activation exacerbates Aβ-associated tau seeding and spreading (2022) (9)
- Sleep evaluation by actigraphy for patients with Alzheimer disease--reply. (2013) (9)
- Blocking the apoE/Aβ interaction ameliorates Aβ-related pathology in APOE ε2 and ε4 targeted replacement Alzheimer model mice (2014) (9)
- High density lipoprotein decreases beta-amyloid toxicity in cortical cell culture. (1997) (9)
- The human trisomy 21 brain: Insights from mouse models of Down syndrome (1996) (8)
- A reverse transcription-polymerase chain reaction study of p75 nerve growth factor receptor gene expression in developing rat cerebellum (1994) (8)
- Multi-Modal Home Sleep Monitoring in Older Adults. (2019) (8)
- Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease. (2016) (8)
- Depression and Alzheimer's Disease Biomarkers Predict Driving Decline. (2018) (8)
- NMNAT3 is protective against the effects of neonatal cerebral hypoxia‐ischemia (2017) (8)
- Cerebrospinal fluid biomarkers, education, brain volume and future cognition (2011) (8)
- Neurobiology of Disease Apolipoprotein E , Especially Apolipoprotein E 4 , Increases the Oligomerization of Amyloid Peptide (2017) (7)
- In vitro cellular respiration at elevated temperatures in developing rat cerebral cortex. (1982) (7)
- Effects of oligomycin on respiration in developing rat brain mitochondria (1977) (7)
- Framework : Toward a Biological Definition of Alzheimer ' s Disease (2018) (7)
- STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks (2021) (7)
- Emerging roles of innate and adaptive immunity in Alzheimer's disease. (2022) (7)
- Alternatives to amyloid for Alzheimer's disease therapies—a symposium report (2020) (7)
- Time savings – realized and potential – and fair compensation for community health workers in Kenyan health facilities: a mixed-methods approach (2015) (7)
- Ruthenium Red Inhibition of In Vitro Lead Effects on Brain Mitochondrial Respiration (1980) (6)
- Cognitively normal APOE ε4 carriers have specific elevation of CSF SNAP-25 (2020) (6)
- Regional age-related atrophy after screening for preclinical alzheimer disease (2021) (6)
- Recent Advances from the Bench Toward the Bedside in Alzheimer's Disease (2015) (6)
- Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation (2017) (6)
- Hallmarks of neurodegenerative diseases (2023) (6)
- TREM2 function impedes tau seeding in neuritic plaques (2019) (6)
- Detection of Subdural Empyema with Radionuclides (1980) (6)
- Correction to Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease [The Journal of Experimental Medicine, 211, 13, (2014), 2487-2496] (2015) (6)
- A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain (2019) (5)
- Maturational Changes in Rabbit Brain Phosphocreatine and Creatine Kinase (1999) (5)
- TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4 (2022) (5)
- The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory (2019) (5)
- Reply to: Fractional synthesis and clearance rates for amyloid β (2011) (5)
- Animal Models of Alzheimer’s Disease (2009) (5)
- Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tau (2021) (5)
- Presymptomatic Alzheimer's disease in the Dominantly Inherited Alzheimer's Network (DIAN) (2012) (5)
- Effects of CD 2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model (2018) (5)
- APOE Antibody Inhibits Aβ‐Associated Tau Seeding and Spreading in a Mouse Model (2022) (5)
- Potential role of endogenous and exogenous amyloid-beta binding molecules in the pathogenesis, diagnosis, and treatment of Alzheimer disease. (2003) (5)
- An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease (2022) (5)
- LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) (5)
- Factors influencing the growth and respiration of rat cerebral astrocytes in primary culture (1981) (5)
- Automated selective disruption of slow wave sleep (2017) (4)
- Adverse driving behaviors are associated with sleep apnea severity and age in cognitively normal older adults at risk for Alzheimer's disease. (2022) (4)
- Creatine kinase and brain energy metabolism : function and disease (2003) (4)
- Using the A/T/N Framework to Examine Driving in Preclinical Alzheimer’s Disease (2018) (4)
- Recapitulation of endogenous 4R tau expression and formation of insoluble tau in directly reprogrammed human neurons. (2021) (4)
- Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer’s disease (2015) (4)
- Cerebrospinal fluid beta-amyloid 42, Tau, and P-tau: confirmation now realization. (2009) (4)
- Modeling cholinergic abnormalities in Down syndrome and Alzheimer's disease. (1991) (4)
- Creatine and nucleoside triphosphates in rat cerebral gray and white matter (1995) (4)
- Mass spectrometry measures of plasma Aβ, tau and P‐tau isoforms’ relationship to amyloid PET, tau PET, and clinical stage of Alzheimer’s disease (2020) (4)
- Late-onset Krabbe disease initially diagnosed as cerebroside sulfatase activator deficiency (1986) (4)
- Endothelial ether lipids link the vasculature to blood pressure, behavior, and neurodegeneration (2021) (4)
- Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) (4)
- Correction: In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS (2012) (4)
- Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Aβ accumulation and plaque-related pathology in a mouse model of amyloidosis (2022) (3)
- Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains (2022) (3)
- Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes. (2022) (3)
- Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1 (2019) (3)
- Ptau-Aβ42 ratio as a continuous trait for biomarker discovery for early stage Alzheimer’s disease in multiplex immunoassay panels of Cerebrospinal fluid (2014) (3)
- Pittsburgh compound B retention and verification of amyloid deposition. (2007) (3)
- CSF biomarkers for secondary prevention trials: why markers of amyloid deposition and neurodegeneration are both important. (2012) (3)
- Corpora amylacea are associated with tau burden and cognitive status in Alzheimer’s disease (2022) (3)
- Amyloid-β ‘seeds’ in old vials of growth hormone (2018) (3)
- Small Molecule Phenotypic Screen Identifies Novel Regulators of LDLR Expression. (2020) (3)
- Human neurons derived from induced pluripotent stem cells as a new platform for preclinical drug screening and development. (2014) (3)
- Alternative Processing of c-Secretase Substrates in Common Forms of Mild Cognitive Impairment and Alzheimer’s Disease: Evidence for c-Secretase Dysfunction (2011) (3)
- Lumbosacral plexopathy secondary to perirectal abscess in a patient with HIV infection (1989) (3)
- Targeting pre-synaptic tau accumulation: a new strategy to counteract tau-mediated synaptic loss and memory deficits (2021) (3)
- Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment (2022) (3)
- Effects of COVID-19 on preclinical and clinical research in neurology: Examples from research on neurodegeneration and Alzheimer’s disease (2021) (3)
- Rat cerebral cortical slice respiration in media of various osmolarities (1982) (3)
- 4. Are autistic spectrum disorders an expression of mitochondrial encephalopathies (2009) (3)
- Task-switching errors show sensitivity to preclinical Alzheimer's disease biomarkers (2015) (3)
- A map of neurofilament light chain species in brain and cerebrospinal fluid and alterations in Alzheimer’s disease (2022) (3)
- Dimebon®: A Clinically Promising Drug for Alzheimer's Disease, Regulates Amyloid-Beta Metabolism in Cultured Cells, In Isolated Nerve Terminals, and In the Interstitial Fluid of the Living Rodent Brain (2009) (3)
- Anti-Aβ antibody target engagement: commentary regarding Watt et al. Acta Neuropathol 127:803–810 (2014) (2014) (3)
- USING THE A/T/N FRAMEWORK TO EXAMINE DRIVING IN PRECLINICAL AD (2018) (3)
- Amyloid imaging and cerebrospinal fluid biomarkers predict driving performance in preclinical Alzheimer's disease (2015) (3)
- Single- nuclei RNA sequencing from human brain to study for Mendelian and sporadic AD (2019) (3)
- Publisher Correction: Dietary salt promotes cognitive impairment through tau phosphorylation (2020) (3)
- Association and expression analyses with SNPs in TOMM40 in Alzheimer's disease (2011) (3)
- Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology (2020) (3)
- Comparison of single-channel EEG, actigraphy, and sleep diary in cognitively normal and mildly impaired older adults (2020) (3)
- Efficiencies in AIDS Programming: The Rhetoric and the Realities (2011) (3)
- CSF sTREM2: marking the tipping point between preclinical AD and dementia? (2016) (2)
- Clinical and Neuropsychological Features of Alzheimer’s Disease (2013) (2)
- Amyloid-beta binding molecule: potential role in the pathogenesis and treatment of Alzheimer disease. (2003) (2)
- ARE WHITE MATTER HYPERINTENSITIES A CORE FEATURE OF ALZHEIMER’S DISEASE OR JUST A REFLECTION OF AMYLOID ANGIOPATHY? EVIDENCE FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (DIAN) (2016) (2)
- Case records of the Massachusetts General Hospital. Case 30-1992. Progressive neurodegenerative disease in a young boy. (1992) (2)
- LONGITUDINAL BIOMARKER CHANGES IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE FROM THE DIAN STUDY (2017) (2)
- Effects of disrupted sleep on abeta and tau pathology and effects of abeta and tau pathology on sleep: A vicious cycle? (2015) (2)
- Human Amyloid Imaging (2008) (2)
- Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study (2023) (2)
- Enamel hypoplasia, bilateral cataracts, and aqueductal stenosis: a new syndrome? (1995) (2)
- Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy (2017) (2)
- The Effect of Low Ionic Strength Extracellular Solutions on the Resting Potential in Skeletal Muscle Fibers (1967) (2)
- B-RAF unlocks axon regeneration (2014) (2)
- An atlas of cortical circular RNA expression in Alzheimer disease brains demonstrates clinical and pathological associations (2019) (2)
- Using Alzheimer's disease blood tests to accelerate clinical trial enrollment (2022) (2)
- Diseases of adenosine triphosphate synthesis in children (2002) (2)
- Heavy Metal Toxicity and Energy Metabolism in the Developing Brain (1985) (2)
- The Ultrastructural Identity of Alzheimer's Pathology: Lessons from Animal Models (2014) (2)
- EFFECTS OF INORGANIC LEAD ON ISOLATED RAT BRAIN MITOCHONDRIAL RESPIRATION (1977) (2)
- Preliminary characterization of long-term reaggregating cultures of trisomy 16 central nervous system. (1992) (2)
- Origins of Alzheimer's Disease: Reconciling CSF biomarker and neuropathology data regarding the temporal sequence of A β and tau involvement (2013) (2)
- Faculty Opinions recommendation of ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. (2012) (1)
- White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantlyinherited Alzheimer’s disease (2018) (1)
- Diurnal oscillation of CSF Aβ and other AD biomarkers (2017) (1)
- In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis (2013) (1)
- Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy (2023) (1)
- Is there a link between the sleep-wake cycle and Alzheimer's pathology? (2015) (1)
- Roles in Alzheimer Disease Apolipoprotein E and Apolipoprotein E Receptors : Normal Biology and Subject Collection The Biology of Alzheimer Disease Animal Models of Alzheimer Disease (2012) (1)
- Active and Passive Immunotherapy Against Tau: Effects and Potential Mechanisms (2016) (1)
- Kir6.2-containing KATP channels are necessary for glucose dependent increases in amyloid-beta and Alzheimer’s-related pathology (2022) (1)
- ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY FOR THE TREATMENT OF EARLY ALZHEIMER’S DISEASE: STUDY DESIGN AND BASELINE CHARACTERISTICS FOR A 96-WEEK, MULTIPLE DOSE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY (2018) (1)
- Abeta conformational change is central to Alzheimer's disease. (2002) (1)
- Sleep Disruption and Risk of Preclinical Alzheimer Disease (P01.081) (2012) (1)
- APOE ε4 Association With Cognition and Alzheimer Disease Biomarkers in Down Syndrome-Implications for Clinical Trials and Treatments for All. (2021) (1)
- DRIVING CESSATION OVER A 22-YEAR PERIOD: DEMENTIA SEVERITY AND CSF BIOMARKERS (2017) (1)
- Algid malaria treated with early goal-directed therapy. (2013) (1)
- Polygenic Risk Score of Sporadic late Onset Alzheimer Disease Reveals a Shared Architecture with the Familial and Early Onset Forms (2017) (1)
- New Conformation-Sensing Imaging Compounds Distinguish Protein Deposits In Apoe ɛ3/ɛ3 Alzheimer's Patients From that in Apoe ɛ4/ɛ4 Alzheimer's Patients (2010) (1)
- P3-232: SNPs in SOAT1, TFAM, and CNDP1 are associated with cerebrospinal fluid amyloid-beta levels (2008) (1)
- Reply to “Inhibition of post-ischemic brain injury by clusterin overexpression” (2001) (1)
- Relationship between brain A{beta} deposition and CSF A{beta}42 several years prior to amyloid positivity (2014) (1)
- IMPACT OF COGNITIVE RESERVE AND PRECLINICAL AD ON LONGITUDINAL DRIVING PERFORMANCE (2017) (1)
- Contents Vol. 18, 1996 (2004) (1)
- Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression. (2022) (1)
- Structural, Functional, and Molecular Neuroimaging Biomarkers for Alzheimer’s Disease (2013) (1)
- Overexpressing Low-Density Lipoprotein Receptor Reduces Tau-Associated Neurodegeneration Via ApoE-Dependent and Independent Mechanisms (2020) (1)
- Reply to “obstructive sleep apnea treatment and amyloid‐β in cerebrospinal fluid” (2019) (1)
- Immigration in science (2020) (1)
- Comparison of plasma and CSF biomarkers in predicting cognitive decline (2022) (1)
- CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease (2022) (1)
- ANTI-AMYLOID-β IMMUNOTHERAPY AS A TREATMENT FOR ALZHEIMER'S DISEASE (2008) (1)
- Plasma ratio of phospho‐ to non‐phospho‐tau at threonine 217 identifies brain amyloid burden as measured by quantitative amyloid PET in the PARIS sub‐study of IDEAS (2022) (1)
- Stealth Attack: Plaque-Specific Antibody Allows for Efficient Aβ Removal without Side Effects (2012) (1)
- EMERGING CSF BIOMARKERS OF NEUROINFLAMMATION, NEURONAL INJURY AND SYNAPTIC INTEGRITY IN THE ADNI COHORT (2016) (1)
- Dual therapy for Aβ amyloidosis in AD: A successful one-two combo (2018) (1)
- Potential role of orexin in the pathogenesis of Alzheimer's disease (2013) (1)
- Sulfonylureas target the neurovascular response to decrease Alzheimer’s pathology (2021) (1)
- CEREBROSPINAL FLUID LEVELS OF AMYLOID BETA AND TAU AS ENDOPHENOTYPES REVEAL NOVEL VARIANTS POTENTIALLY INFORMATIVE FOR ALZHEIMER'S DISEASE (2016) (1)
- Synaptic Transmission Dynamically Modulates Interstitial Fluid Amyloid-β Levels (2008) (1)
- Potential Role of Endogenous and Exogenous Ab Binding Molecules in Ab Clearance and Metabolism (2013) (1)
- Blocking the Interaction between Apolipoprotein E and Ab Reduces Intraneuronal Accumulation of Ab and Inhibits (2013) (1)
- Trisomy of human chromosome 21 enhances amyloid-beta 3 deposition independently of an extra copy of APP (vol 141, pg 2457, 2018) (2019) (1)
- INCIDENCE OF HIGH GRADE QTCF PROLONGATION AND ITS MANAGEMENT AMONG PATIENTS UNDERGOING TREATMENT FOR DRUG RESISTANT TUBERCULOSIS (DR-TB): CASE SERIES. (2021) (1)
- Measurement of apolipoprotein E and amyloid β clearance rates in the mouse brain using bolus stable isotope labeling (2012) (1)
- Science Translational Medicine Podcast: 6 April 2011 (2011) (1)
- Aquaporin‐4 expression is altered around the lateral ventricle in correlation with beta‐amyloid plaque expression in a transgenic mouse model of Alzheimer‘s Disease (2008) (1)
- Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer’s disease in a memory clinic cohort (2015) (1)
- BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD (2017) (1)
- BLOOD AMYLOID-BETA PREDICTS AMYLOID PET CONVERSION (2019) (1)
- Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2022) (1)
- Meningeal lymphatics modulate microglial activation and immunotherapy in Alzheimer’s disease (2022) (1)
- Multiple γ-secretase product peptides are coordinately increased in concentration in the cerebrospinal fluid of a subpopulation of sporadic Alzheimer’s disease subjects (2012) (1)
- Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2 (2014) (1)
- A β 1-15/16 as a marker for γ -secretase inhibition in Alzheimer’s disease (2013) (1)
- In Memoriam of John T. Trojanowski, MD, PhD 1946-2022 (2022) (1)
- Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs (2022) (1)
- APP-Based Transgenic Models: The PDAPP Model (2011) (1)
- Lentiviral vector delivery of orexin gene to study potential role of orexin and sleep modulation in the pathogenesis of alzheimer’s disease (2018) (1)
- Detecting preclinical markers of dementia: The power of sustained attention and mind-wandering (2012) (1)
- Glial contributions to neurodegeneration in tauopathies (2017) (0)
- Constructions anti-tau (2016) (0)
- Pathogenesis, Diagnosis, and Treatment of Vascular and Mixed Dementias (2013) (0)
- Activated astrocytes suppress amyloid plaque pathogenesis in APP/PS1 mice (2009) (0)
- The informed road map to prevention of Alzheimer Disease: A call to arms (2021) (0)
- Editorial Board (2011) (0)
- Oral Sessions: O3-03: Biomarkers: Temporal Sequence of Biomarkers (2013) (0)
- PLASMA Aβ42/Aβ40 PREDICTS HIPPOCAMPAL ATROPHY (2019) (0)
- CONCENTRATIONS AND STABLE ISOTOPE LABEL KINETICS OF HUMAN PLASMA AMYLOID BETA (2017) (0)
- Murine versus human apolipoprotein E4: differential facilitation of and co-localization in cerebral amyloid angiopathy and amyloid plaques in APP transgenic mouse models (2015) (0)
- Automated slow wave sleep disruption in middle-aged adults (2015) (0)
- Author Correction: FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease (2022) (0)
- Editorial Board (2007) (0)
- Evidence that the gut microbiota regulates progression of neurodegeneration in a mouse model of tauopathy, in a sex‐ and ApoE isoform‐dependent manner (2021) (0)
- New insights into the role of TREM2 in Alzheimer’s disease (2018) (0)
- Alzheimer’s treatment may be more effective for people at highest risk (2020) (0)
- Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics (2019) (0)
- Development of a New Antibody-Based Diagnostic Approach for the Earlier Diagnosis and Treatment of Alzheimer ’ s Disease (2019) (0)
- Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight (2018) (0)
- The interaction of APOE genotype and amyloid‐β PET predicts PET but not CSF measures of tauopathy in regions of high APOE mRNA expression (2021) (0)
- 3-12-15 ApoE isoforms do not modify neuronal susceptibility to injury by certain excitotoxic or apoptotic agents in cortical cell culture (1997) (0)
- Neurotrophic Factors andNeurologic Disease (1994) (0)
- P2-141 Identification of CSF biomarkers for Alzheimer’s disease using proteomic approaches (2006) (0)
- Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism (2018) (0)
- CRITICAL ANALYSIS OF BIOMARKER CUTOFFS IN ALZHEIMER DISEASE (2016) (0)
- IMMU-35. TREM2 RESTRAINS ANTI-TUMOR CELL ACTIVITY OF MYELOID CELLS IN GLIOBLASTOMA (2022) (0)
- 25-HYDROXYCHOLESTEROL AMPLIFIES MICROGLIAL NEUROINFLAMMATORY SIGNALING IN AN APOE ISOFORM-DEPENDENT MANNER (2018) (0)
- Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers (2015) (0)
- P2-291 ABCA1 knock-out mice have decreased apoeinbrainand CSF and secrete cholesterol poor apoE-containing HDL from astrocytes in vitro (2004) (0)
- Contents Vol. 22, 2000 (2000) (0)
- PL-05-01 Studies of amyloid-β metabolism: Insights into pathogenesis, diagnosis, and treatment of Alzheimer’s disease (2006) (0)
- Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease (2019) (0)
- Senescent glia spell trouble in Alzheimer’s disease (2019) (0)
- Regional cerebral glucose metabolism is associated with interstitial fluid Aβ concentration and plaque deposition in Tg2576 mice (2010) (0)
- Correlation of the AD8: an Informant-Based Dementia Screening Tool with Amyloid Imaging and CSF Biomarkers of Alzheimer Disease (2010) (0)
- FROM THE ALZHEIMER ’ S ASSOCIATION INTERNATIONAL CONFERENCE 2017 ALZHEIMER ’ S ASSOCIATION LAUNCHES $ 20 MILLION LIFESTYLE INTERVENTION TRIAL IN THE U . S . TO PREVENT COGNITIVE DECLINE – (2017) (0)
- Experimental Animal Models of Alzheimer’s Disease (2013) (0)
- PREDICTION OF INCIDENT DEMENTIA: LONGITUDINAL BIOMARKER AND CLINICAL CHANGES BEFORE AND AFTER (2017) (0)
- P4-127 EXPLORING THE UTILITY OF CSF NEUROGRANIN LEVELS IN AN ALZHEIMER’S DISEASE CLINICALTRIAL (2016) (0)
- Schindler Supplemental Materials (2019) (0)
- Test method for alzheimer (2002) (0)
- AMPA-ergic regulation of amyloid-β levels in an Alzheimer’s disease mouse model (2018) (0)
- Humanized antibodies which sequester amyloid beta peptide (2001) (0)
- WHAT GOES UP MUST COME DOWN: LONGITUDINAL DECLINE IN CEREBROSPINAL FLUID TAU PEPTIDES IS ASSOCIATED WITH PROGRESSIVE CORTICAL ATROPHY (2018) (0)
- APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) (0)
- In memoriam: William M. Landau, MD (2018) (0)
- AND PROTEOMICS INTEGRATIVE PROTEOMICS LINKS CEREBROSPINAL FLUID BIOMARKERS TO PATHOLOGICAL NETWORKS IN THE ALZHEIMER’S DISEASE BRAIN HIPPOCAMPAL ATROPHY (2019) (0)
- Longitudinal changes in cerebrospinal fluid biomarkers of Alzheimer's disease during middle-age in cognitively normal individuals with a positive family history (2012) (0)
- Clinical Features and Pathogenesis of Prion Disease (2013) (0)
- 1 NIAAA Research Framework : Towards a Biological Definition of Alzheimer ’ s Disease 1 2 draft 11-2 7-17 3 4 (2017) (0)
- LONGITUDINAL AMYLOID DEPOSITION AND HIPPOCAMPAL VOLUME IN SUSPECTED NON-ALZHEIMER PATHOPHYSIOLOGY AND PRECLINICAL ALZHEIMER'S DISEASE (2016) (0)
- Insights from new in vivo models of TREM2 variants (2023) (0)
- Jee Hoon Roh in Mice with Alzheimer ' s Disease Pathology-Amyloid β Disruption of the Sleep-Wake Cycle and Diurnal Fluctuation of (2013) (0)
- STAT3 inhibitor mitigates cerebral amyloid angiopathy and parenchymal amyloid plaques while improving cognitive functions and brain networks (2021) (0)
- sequester amyloid beta peptide humanized antibodies (2001) (0)
- S5-01-03: Biomarkers for prevention trials (2008) (0)
- Amyloid-β ‘seeds’ in old vials of growth hormone (2018) (0)
- Views CSF sTREM 2 : marking the tipping point between preclinical AD and dementia ? (2016) (0)
- P3-296: Assessment of human apolipoprotein E and Aβ clearance rate in vivo through use of stable isotope-labeling and tandem mass spectrometry (2008) (0)
- P2-202 URT: A new diagnostic approach for the early diagnosis of the Alzheimer’s disease (2006) (0)
- Analysis of in vivo turnover of tau in a mouse model of tauopathy (2015) (0)
- P2-016: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease (2008) (0)
- Hemorrhage in Mouse Models of Cerebral Amyloid Angiopathy (2015) (0)
- Subject Index Vol. 18, 1996 (1996) (0)
- molecules for sleep regulation Translational profiling of hypocretin neurons identifies candidate Material Supplemental (2013) (0)
- O1-03-04 The LDL receptor regulates levels of CNS and Alzheimer's disease-like pathology (2004) (0)
- RELATING PET AND CSF MEASURE OF TAU PATHOLOGY (2016) (0)
- Accuracy of Clinical Diagnosis of Dementia of the Alzheimer Type: Impact of Longitudinal Follow-up and Inclusion of CSF Biomarkers (2010) (0)
- Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. (2023) (0)
- β Peptide Clearance (2011) (0)
- O3-01-07 Relationship between in vivo amyloid imaging with 11C-PIB and CSF Aβ42 (2006) (0)
- 0326 Influence of Sleep and Cardiovascular Health on Cognitive Outcomes in Older Adults (2022) (0)
- Dietary salt promotes cognitive impairment through tau phosphorylation (2019) (0)
- Editorial Board (2004) (0)
- Reply (2010) (0)
- The Novel Neuronal Injury Marker, Visinin-like Protein-1 (VILIP-1), as a Diagnostic and Prognostic Marker in Alzheimer's Disease (2010) (0)
- Effects of CD2-associated protein deficiency on amyloid-β in neuroblastoma cells and in an APP transgenic mouse model (2015) (0)
- Faculty Opinions recommendation of Dynamics of retrieval strategies for remote memories. (2012) (0)
- Plaques Associated with Tangles in Mouse Models of AD (2002) (0)
- Alzheimer Aβ Vaccination of Rhesus Monkeys (Macaca Mulatta) (2004) (0)
- White matter hyperintensities and the mediating role of cerebral amyloid angiopathy in dominantly-inherited Alzheimerâ•Žs disease (2019) (0)
- EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: FINDINGS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2017) (0)
- CSF and blood plasma mass spectrometry measures of Aβ, tau, and NfL species and longitudinal relationship to preclinical and clinical staging of amyloid and tau aggregation and clinical stage of Alzheimer’s disease (2021) (0)
- A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) (0)
- Potter Presenilin Mutation Carriers 42 Production , Exchange , and Loss in β Increased in Vivo Amyloid (2013) (0)
- Gamma-secretase dysfunction in sporadic Alzhemer's disease suggested by p3-Alc peptide, metabolic product of Alcadein (2010) (0)
- Diagnostic utility of CSF biomarkers in an Alzheimer's clinic (2011) (0)
- Need to Pinpoint Major Speci fi c Pathologies and Circuit Dysfunction in Neurodegenerative Diseases over the Life Span and to Identify Dysfunctional Circuits (2015) (0)
- Review Article Tau: From research to clinical development (2016) (0)
- Author response. (2013) (0)
- Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation (2016) (0)
- Editorial Board (2004) (0)
- APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression (2022) (0)
- Correlation of the AD8, an informant-based dementia screening tool, with amyloid imaging and CSF biomarkers of Alzheimer disease (2010) (0)
- Targeting tauopathy with engineered tau-degrading intrabodies (2019) (0)
- P3-047 Probing for antecedent biomarkers of Alzheimer's disease through analysis of cerebrospinal fluid from middle-aged individuals (2004) (0)
- Corpora amylacea are associated with tau burden and cognitive status in Alzheimer’s disease (2022) (0)
- Publisher Correction: Dietary salt promotes cognitive impairment through tau phosphorylation (2020) (0)
- The Role of Big Data in Understanding Late-Life Cognitive Decline E Unum, Pluribus (2017) (0)
- Apolipoprotein E, Alzheimer’s disease and cerebral amyloid angiopathy: Effects of apoE on amyloid-B metabolism suggest underlying mechanisms and potential treatments (2005) (0)
- Podium Presentations: Thursday, July 23, 2015 P326 O5-05-03 NEUROGRANIN, A CSF BIOMARKER FOR SYNAPTIC LOSS, PREDICTS DECLINE TO DEMENTIA DUE TO ALZHEIMER’S DISEASE (2015) (0)
- Book Review Neurology of Hereditary Metabolic Diseases of Children Third edition. By Gilles Lyon, Edwin H. Kolodny, and Gregory M. Pastores. 542 pp., illustrated. New York, McGraw-Hill, 2006. $165. 978-0-07-144508-5 (2007) (0)
- Identifying multi-analyte CSF biomarkers for Alzheimer’s disease in a multi-cohort study (2013) (0)
- Assays for alzheimer's disease (2002) (0)
- EXPLORING THE UTILITY OF CSF NEUROGRANIN LEVELS IN AN ALZHEIMER’S DISEASE CLINICAL TRIAL (2016) (0)
- Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation (2017) (0)
- Murine roseolovirus does not accelerate amyloid-β pathology and human roseoloviruses are not over-represented in Alzheimer disease brains (2022) (0)
- LONGITUDINAL CHANGES IN CEREBROSPINAL FLUID BIOMARKERS OF ALZHEIMER'S DISEASE: FINDINGS FROM A COGNITIVELY NORMAL, MIDDLE-AGED COHORT (2014) (0)
- Identification and validation of novel cerebrospinal fluid protein biomarkers for early Alzheimer's disease using proteomics and ELISA: a multi-institutional collaborative study (2010) (0)
- IC-P-178 OCCUPATIONAL COMPLEXITY, COGNITIVE RESERVE, ANDWHITE MATTER HYPERINTENSITIES: FINDINGS FROM THE WISCONSIN REGISTRY FOR ALZHEIMER’S PREVENTION (2019) (0)
- Reply (2017) (0)
- Synaptic activity, amyloid-β and Alzheimer’s disease (2006) (0)
- REGIONAL PIB DEPOSITION AND CSF Aβ42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY (2014) (0)
- Correction: Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism (2022) (0)
- P4-268: APP endocytosis is required for synaptic-dependent release of amyloid-beta in vivo (2008) (0)
- Faculty of 1000 evaluation for Assessment of α-synuclein secretion in mouse and human brain parenchyma. (2011) (0)
- P2-068 Age-independent and age-dependent learning and memory abnormalities in PDAPP mice on a C57BL/6 background (2004) (0)
- Academic spin-out companies (2015) (0)
- ASSOCIATEDWITH A SPECIFIC PATTERN OF CEREBRALWHITE MATTER INJURY IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT ENROLLED TO THE ADNI STUDY (2015) (0)
- Strategic site selection for placement of HIV early infant diagnosis point-of-care technology within a national diagnostic network in Lesotho (2021) (0)
- CRITICAL ANALYSIS OF BIOMARKER CUTOFFS IN ALZHEIMER'S DISEASE (2016) (0)
- LRP1 is a neuronal receptor for α-synuclein uptake and spread (2022) (0)
- Erratum: Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease (Science Translational Medicine DOI: 10.1126/scitranslmed.aau6550) (2020) (0)
- NEUROPSYCHIATRIC SYMPTOMS AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE (2017) (0)
- ABBV-8E12, A HUMANIZED ANTI-TAU MONOCLONAL ANTIBODY, FOR TREATING EARLY ALZHEIMER’S DISEASE: UPDATED DESIGN AND BASELINE CHARACTERISTICS OF A PHASE 2 STUDY (2019) (0)
- EUROPEAN BEHAVIOURAL AND NEURAL GENETICS SOCIETY FIRST ANNUAL GENERAL MEETING September 29-October 1 , 1997 Orléans , France Provisional Executive Committee (2007) (0)
- O3-02-02: Update on the relationship between in vivo amyloid imaging with C-PIB and CSF Aβ42 (2008) (0)
- Role of APOE in Alzheimer's disease-like neurodegeneration (2000) (0)
- P2-294: Microarray profiling reveals autoantibody reactivities against abnormal amyloid peptide conformations decline with age and in Alzheimer's disease (2008) (0)
- In Memoriam of John T. Trojanowski, MD, PhD 1946-2022 (2022) (0)
- IC-P-054 Relationship between in vivo amyloid imaging with 11C-PIB and CSF Aβ42 (2006) (0)
- Subject Index Vol. 22, 2000 (2000) (0)
- P1-240 Static and dynamic AFM studies of β-amyloid aggregates and their interaction with relevant biological macromolecules (2004) (0)
- EXAMINING THE ASSOCIATION BETWEEN INTRAINDIVIDUAL MEANS AND STANDARD DEVIATIONS OF REACTION TIME AND PRECLINICAL ALZHEIMER DISEASE (2019) (0)
- Neurobiology of Disease Bcl-x Pre-mRNA Splicing Regulates Brain Injury after Neonatal Hypoxia-Ischemia (2019) (0)
- CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD (2022) (0)
- Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction (2023) (0)
- Gut microbiota regulates neuroinflammation and progression of neurodegeneration in a mouse model of tauopathy (2022) (0)
- Potential role of the sleep-wake cycle in the pathogenesis of Alzheimer's disease (2012) (0)
- IC-01-01: Cortical binding of Pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease (2008) (0)
- Plasma and Cerebrospinal Fluid Markers in the DIAN Study of Autosomal-Dominant Alzheimer’s Disease (2011) (0)
- PRECLINICAL ALZHEIMER’S DISEASE PREDICTS LONGITUDINAL ONSET OF DRIVING DIFFICULTIES AMONG COGNITIVELY NORMAL PERSONS (2016) (0)
- P2-063 In vivo dynamics of amyloid associated neuritic dystrophy before and after anti-Aβ immunotherapy (2004) (0)
- Alzheimer disease. Edited by Robert D. Terry, Robert Katzman, and Katherine L. Bick, New York, Raven Press, 1994 472 pp, illustrated, $139.00 (1994) (0)
- APOLIPOPROTEIN E GENOTYPE DIFFERENTIALLY MODULATES EFFECTS OF ANTI-AB IMMUNOTHERAPY (2016) (0)
- Co-aggregation with Apolipoprotein E modulates the function of Amyloid-β in Alzheimer’s disease (2021) (0)
- Lack of hepatic apoE does not influence early Aβ deposition: observations from a new APOE knock-in model (2019) (0)
- Pattern Discovery in Brain Imaging Genetics via SCCA Modeling with a Generic Non-convex Penalty (2017) (0)
- Author Correction: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. (2023) (0)
- TRISOMY 21 CAUSES A DEFICIT IN LYSOSOMAL CATHEPSINS AND ALTERS APP/Aβ PROCESSING, INDEPENDENTLY OF AN EXTRA COPY OF APP (2017) (0)
- A surrogate marker for Aβ42 production in the CNS (2009) (0)
- CSF tau phosphorylation at sites 217 and 205 mediate the relationship between PET amyloid and downstream AD markers (2022) (0)
- Novel fluid biomarkers for brain amyloid and dementia risk in presymptomatic Alzheimer disease (2015) (0)
- BRAIN AEROBIC GLYCOLYSIS AND AD PATHOLOGY BIOMARKERS IN AUTOSOMAL DOMINANT AD (2017) (0)
- Medication Use as a Confounding Factor in the Use of the Cerebrospinal Fluid tau/β-Amyloid42 Ratio—Reply (2007) (0)
- A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis (2021) (0)
- Novel genetic risk factor for Alzheimer's disease progression [abstract] (2010) (0)
- Acute hyper- and hypoglycemia uncouples the metabolic cooperation between glucose and lactate to disrupt sleep (2022) (0)
- Cerebrospinal fluid biomarkers predict longitudinal decline in attentional control in the adult children study (2015) (0)
- Current Therapies for Alzheimer’s Disease (2013) (0)
- Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE (2019) (0)
- Lecanamab Ushers in a New Era of Anti‐Amyloid Therapy for Alzheimer's Disease (2023) (0)
- Methods for measuring in vivo biomolecules from the nervous system (2006) (0)
- 25-Hydroxycholesterol amplifies microglial IL-1β production in an apoE isoform-dependent manner (2020) (0)
- TREM2-MEDIATED EARLY RESPONSE BY RESIDENT MICROGLIA LIMITS DIFFUSION AND TOXICITY OF AMYLOID PLAQUES (2016) (0)
- Early pathological changes due to Alzheimer's disease are detected by graph theoretical measures of functional connectivity (2013) (0)
- Analysis Method for Alzheimer's disease (2002) (0)
- Mapping Sleep’s Oscillatory Events as a Biomarker of Alzheimer’s Disease (2023) (0)
- 2018 NIA-AA Research Framework to Investigate the Alzheimer ’ s Disease Continuum 1 2 DRAFT 7-18-17 3 4 5 Clifford (2017) (0)
- P1-350: Effects of rare genetic variations in ABCA1 on apolipoprotein E levels in human cerebrospinal fluid (2006) (0)
- Lewy Body Dementias (2013) (0)
- P1-149 CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER’S DISEASE THE (2014) (0)
- 0845 INTERPRETING IN-HOME SLEEP BIOMARKERS BASED ON POLYSOMNOGRAPHY REFERENCE VALUES (2017) (0)
- ApoE Alzheimer’s Disease Aβ-amyloid plaque morphology varies according to APOE isotype (2023) (0)
- Dural lymphatics regulate clearance of extracellular tau from the CNS (2019) (0)
- Leo J. Neuringer (1994) (0)
- P3-026 Identification of biomarkers for Alzheimer's disease using proteomics approaches (2004) (0)
- OpposingSynapticRegulationofAmyloid-Metabolismby NMDAReceptorsInVivo (2011) (0)
- Neurodegeneration and gene dysregulation: studies utilizing the mouse trisomy 16 model of Down syndrome. (1992) (0)
- Genome-wide association studies using cerebrospinal fluid biomarkers as an endophenotype for Alzheimer's disease (2012) (0)
- Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease (2015) (0)
- SYNERGISTIC AND MEDIATIONAL EFFECTS OF ALZHEIMER'S DISEASE BIOMARKERS ON A COGNITIVE MEASURE (2014) (0)
- Test method for alzheimer's disease. (2002) (0)
- 25‐Hydroxycholesterol modulates tau‐mediated neurodegeneration and microglial chemotaxis and phagocytosis (2021) (0)
- humanized antibodies which sequester Abeta. (2001) (0)
- Apolipoprotein E O-glycosylation is associated with amyloid plaques and APOE genotype (2023) (0)
- P3-088: Identification of potential biomarkers for Alzheimer's disease in cerebrospinal fluid using two-dimensional difference gel electrophoresis and tandem mass spectrometry: A multi-institutional collaborative study (2008) (0)
- Effects of human LDLR overexpression on apoE-related tau pathology and brain dysfunction (2020) (0)
- Effects of a Peripheral Anti-Aβ Antibody on Plasma and CNS Aβ Clearance (2003) (0)
- Castellano 2011 Sci Transl Med-1 (2015) (0)
- Proteomic Clusters Underlie Heterogeneity in Preclinical AD Progression (2022) (0)
- Cerebrospinal fluid beta-amyloid 42, tau, phosphorylated tau 181, and resting state functional connectivity (2013) (0)
- Reply to "Do repetitive Valsalva maneuvers reduce glymphatic clearance?" (2016) (0)
- Novel Pentameric ThiopheneDerivatives for in Vitro and in Vivo Optical Imagingof aPlethora of ProteinAggregates inCerebral Amyloidoses (2009) (0)
- 0299 Effect of Glycemic Extremes on Sleep/wake and Alzheimer’s Disease Pathophysiology (2019) (0)
- BETA-AMYLOID oligomerization in Alzheimer's DISEASE DEMENTIA versus high pathology controls (2012) (0)
- Early Clinical Utility Data of a Blood Biomarker Test in the Evaluation of Mild Cognitive Impairment (2021) (0)
- Analysis of cerebrospinal fluid beta-amyloid and apolipoprotein E lipoproteins in APPV717F transgenic mice (2000) (0)
- Synthetic human apoE particles differentially regulate brain interstitial amyloid-beta levels (2011) (0)
- PRECLINICAL TO CLINICAL TRANSLATION FOR TAU THERAPEUTICS (2016) (0)
- Faculty Opinions recommendation of Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening. (2011) (0)
- Human glia‐specific functional dysregulations affected by APOE ε4 risk of Alzheimer's disease (2020) (0)
- Longitudinal CSF changes in markers of neurodegeneration and utilization of these markers in predicting conversion from normal cognition to cognitive impairment (2012) (0)
- ASSOCIATION OF AD PATHOLOGY AND NON-RAPID EYE MOVEMENT SLOW WAVE ACTIVITY (2018) (0)
- TAU IMAGING RELATIONSHIPS WITH AMYLOID B IMAGING, CSF TAU/AB42, AND COGNITION IN ALZHEIMER’S DISEASE (2016) (0)
- Global system segregation enhances reserve in normal aging and Alzheimer’s disease (2020) (0)
- Comparison of nia-aa preclinical Alzheimer's disease staging with CSF and neuroimaging biomarkers (2015) (0)
- Evaluation of pre-analytical and analytical factors that contribute to variability in CSF biomarker levels (2013) (0)
- Diagnostic markers: Detection of preclinical pathology, prognostic capabilities, and dynamic metabolism of Abeta and tau (2010) (0)
- P3-095: Levels of CSF biomarkers predict rate of cognitive decline in individuals with very mild dementia of the Alzheimer's type (2008) (0)
- Cerebrospinal fluid beta-amyloid 42, tau, ptau181 and resting state functional connectivity (2013) (0)
- High resolution hydration analysis as a tool for the early diagnosis of misfolding disorders (2005) (0)
- EFFECTS OF SYNAPTIC ACTIVITY ON Aβ AND TAU FROM PRECLINICAL IN VIVO STUDIES: SIMILARITIES, DIFFERENCES, AND IMPLICATIONS (2017) (0)
- P2-143 Quantitation of in vivo amyloid-beta synthesis and clearance rates in humans using stable isotope labeling and mass spectrometry (2006) (0)
- Development of a New Antibody-Based Diagnostic Approach for the Earlier Diagnosis and Treatment of AlzheimerTMs Disease ΠYoung Scientists Journal (2020) (0)
- LONGITUDINAL COURSE OF PRECLINICAL AD USING THE A/T/N FRAMEWORK (2018) (0)
- P3-065: Development of a solid phase extraction protocol for extracting peptides from cerebrospinal fluid in conjunction with tandem mass spectrometry to identify novel biomarkers for Alzheimer's disease (2008) (0)
- O2-06-03: Late-onset Alzheimer's Disease–associated SNPS in TOMM40 and APOE have different effects on cerebrospinal fluid amyloid-beta levels (2008) (0)
- REGIONAL PIB DEPOSITION AND CSF AB42 LEVELS SEVERAL YEARS PRIOR TO AMYLOID POSITIVITY (2014) (0)
- EFFECTS OF APOE ON TAU MEDIATED NEURODEGENERATION (2018) (0)
- P4-081: Diurnal fluctuation of amyloid-β in the brain interstitial fluid of young Tg2576 mice (2008) (0)
- Plasma multianalyte profiling of mild cognitive impairment and Alzheimer's disease in two academic centers and the Alzheimer's Disease Neuroimaging Initiative (2011) (0)
- Using cerebrospinal fluid markers to identify stages of National Institute on Aging and Alzheimer’s Association proposed criteria for preclinical Alzheimer's disease and its prognosis (2013) (0)
- Amyloid immunotherapy, extra-CNS actions (2005) (0)
- p3-Alc peptides produced by covariant processing of Alcadein and APP implicate γ-secretase dysfunction in sporadic Alzheimer's disease (2009) (0)
- 63 Electron transport chain abnormalities in lymphoblasts from autistic children (2010) (0)
- LONGITUDINAL CLINICAL AND BIOMARKER CHANGES IN DOMINANTLY INHERITED ALZHEIMER'S DISEASE: THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2016) (0)
- DYNAMIC RELATIONSHIPS BETWEEN “BIG FIVE” PERSONALITY TRAITS, ALZHEIMER’S DISEASE BIOMARKERS, AND COGNITION IN AUTOSOMAL DOMINANT ALZHEIMER’S DISEASE (2016) (0)
- Live discussion: Protein folding and neurodegeneration: Biophysics to the rescue? 1 (2004) (0)
- 1580 HYPERTHERMIA-INDUCED SEIZURES IN THE RAT PUP (1981) (0)
- O4-06-07 MMP-9 degrades fibrilllar Abeta in vitro and compact plaques in situ (2006) (0)
- Soluble Aβ clearance from the brain interstitial fluid of PDAPP mice is human apoE isoform-dependent (2010) (0)
- METABOLISM OF CNS DERVED BOMOLECULES IN VIVO (2017) (0)
- Epidemiology of Alzheimer Disease (2012) (0)
- A novel diagnostic and prognostic fluid biomarker for early Alzheimer's disease: YKL-40 (2010) (0)
- Interrelationships of Energy Metabolism to Oxidative Damage and Neurodegeneration (1998) (0)
- A single dose of the γ-secretase inhibitor semagacestat alters the cerebrospinal fluid peptidome in humans (2016) (0)
- P3-021 Plasma Aβ levels following Aβ antibody administration in young mice predicts brain amyloid burden at an older age (2004) (0)
- Amyloid‐&bgr; Binding Molecule: Potential Role in the Pathogenesis and Treatment of Alzheimer Disease (2003) (0)
- Systematic characterization of brain cellular crosstalk reveals a novel role for SEMA6D in TREM2-associated microglial function in Alzheimer’s disease (2023) (0)
- Neurodegenerative Diseases: What Is to Be Done? (2015) (0)
- AAV-MEDIATED EXPRESSION OF HUMAN LDLR MARKEDLY REDUCES AMYLOID DEPOSITION IN A MOUSE MODEL OF AMYLOID-β AMYLOIDOSIS (2017) (0)
- Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy (2023) (0)
- Erratum: Cerebrospinal fluid sulfatide is decreased in subjects with incipient dementia (Annals of Neurology (2003) 54 (115-119)) (2003) (0)
- Methods of determining the parts of amyloid beta in blood (2011) (0)
- Editorial Board and Contents (2018) (0)
- CSF VILIP-1 AND YKL-40, NOVEL CANDIDATE BIOMARKERS TO DIAGNOSE, PREDICT, AND MONITOR ALZHEIMER'S DISEASE (2014) (0)
- Are CSF biomarkers ready for prime time as diagnostics for Alzheimer disease? Interview by Rebecca Voelker. (2010) (0)
- DEPRESSION AND ALZHEIMER DISEASE BIOMARKERS PREDICT DRIVING DECLINE (2018) (0)
- Alzheimer’s Disease Therapeutics Targeting Apolipoprotein E (2016) (0)
- A vaccine for Alzheimer's disease? (2006) (0)
- P3-102: Correlating hippocampal structure and CSF proteins in early dementia of the Alzheimer type (2008) (0)
- CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE (2017) (0)
- O1-03-05: Dynamics of compact plaque growth in APP/PS1 mice (2008) (0)
- Sleep deprivation exacerbates microglial reactivity and Aβ deposition in a TREM2-dependent manner in mice (2023) (0)
- A Review of the Current Understanding and Treatment of Alzheimer's Disease (2014) (0)
- APOE4 plays a role in Abeta-mediated synapse loss in Alzheimer's disease (2011) (0)
- Early pathological changes due to Alzheimer's disease are detected by graph theoretical measures of functional connectivity (2013) (0)
- P2-296 Apolipoprotein E delays Aβ elimination in the brain interstitial fluid of young PDAPP mice (2004) (0)
- Author Correction: Human and mouse single-nucleus transcriptomics reveal TREM2-dependent and TREM2-independent cellular responses in Alzheimer’s disease (2020) (0)
- EXAMINING LONGITUDINAL NEUROIMAGING PATTERNS IN AUTOSOMAL DOMINANT ALZHEIMER DISEASE: RESULTS FROM THE DOMINANTLY INHERITED ALZHEIMER NETWORK (2017) (0)
- ALZHEIMER’S DISEASE Advances in Genetics, Molecular and Cellular Biology ALZHEIMER’S DISEASE Advances in Genetics, Molecular and Cellular Biology (2013) (0)
- ApoE: PHYSIOLOGIC FUNCTIONS AND RISK FACTOR FOR ALZHEIMER’S DISEASE (2020) (0)
- Biomarkers for Alzheimer's disease: the dilemma of silent disease (2009) (0)
- Clinical Features and Pathogenesis of Frontotemporal Dementia (2013) (0)
- Interactive effects of a sedentary lifestyle and the APOE e4 allele on amyloid deposition (2011) (0)
- 36 Effect of Anti-ApoE antibodies on Aβ pathology and accumulation (2012) (0)
- omers can disrupt normal neuronal homeostasis by triggering focal accumulation of axonal tau, loss of the polarized distribution of tau and dysregulation of fast axonal transport (2017) (0)
This paper list is powered by the following services:
Other Resources About David M. Holtzman
What Schools Are Affiliated With David M. Holtzman?
David M. Holtzman is affiliated with the following schools:
- University of California, Berkeley
- University of Eastern Finland
- Northwestern University
- University of Chicago
- University of California, San Francisco
- Washington University in St. Louis
- Massachusetts Institute of Technology
- Stanford University
- Johns Hopkins University
- University of Washington
- Harvard University
